Skip to content
Advertisement

A vial of the Phase 3 Novavax coronavirus vaccine is prepared for use in a trial at St. George's University hospital in London, Oct. 7, 2020. In a statement on Thursday March 31, 2022, the pharmaceutical Novavax said it asked the European Medicines Agency to extend the authorization of its coronavirus vaccine to children aged 12 to 17 amid a surge of disease across the continent. (AP Photo/Alastair Grant, File)

A vial of the Phase 3 Novavax coronavirus vaccine is prepared for use in a trial at St. George's University hospital in London, Oct. 7, 2020. In a statement on Thursday March 31, 2022, the pharmaceutical Novavax said it asked the European Medicines Agency to extend the authorization of its coronavirus vaccine to children aged 12 to 17 amid a surge of disease across the continent. (AP Photo/Alastair Grant, File)

Featured Photo Galleries